Voyager Therapeutics is expanding its Alzheimer's disease franchise with a program focused on modulating APOE using TRACER technology.
1 report, 1 independent
Updated Jul 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Voyager Therapeutics is expanding its Alzheimer's disease franchise with a program focused on modulating APOE using TRACER technology.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Voyager Therapeutics (United States)
company in Cambridge, United States
Nothing else this week.
-
Tracer
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireVoyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach - New program combines IV-delivered TRACER™ capsid with